Skip to main content

Advertisement

Table 2 Adverse events experienced by at least 10% of patients by severity

From: STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

AE, n (%) Total (N = 30) Grade 1 Grade 2 Grades 3 and 4
Any AE, highest grade experienceda 29 (97) 2 (7) 8 (27) 18 (60)
ALT elevation 12 (40) 5 (17) 5 (17) 2 (7)
AST elevation 12 (40) 7 (23) 4 (13) 1 (3)
Fatigue 11 (37) 4 (13) 5 (17) 2 (7)
Thrombocytopenia 9 (30) 2 (7) 2 (7) 5 (17)
Nausea 6 (20) 2 (7) 3 (10) 1 (3)
Anemia 5 (17) 2 (7) 2 (7) 1 (3)
Hypomagnesemia 5 (17) 5 (17) 0 0
Peripheral edema 5 (17) 3 (10) 2 (7) 0
Alkaline phosphatase elevation 4 (13) 3 (10) 1 (3) 0
Dysphagia 4 (13) 3 (10) 0 1 (3)
Dyspnea 4 (13) 2 (7) 2 (7) 0
Hypercalcemia 4 (13) 1 (3) 2 (7) 1 (3)
Hypokalemia 4 (13) 3 (10) 0 1 (3)
Hyponatremia 4 (13) 3 (10) 0 1 (3)
Neutropenia 4 (13) 1 (3) 0 3 (10)
Vomiting 4 (13) 4 (13) 0 0
Abdominal pain 3 (10) 1 (3) 2 (7) 0
Anorexia 3 (10) 1 (3) 2 (7) 0
Asthenia 3 (10) 1 (3) 1 (3) 1 (3)
Constipation 3 (10) 3 (10) 0 0
Creatinine elevated 3 (10) 2 (7) 1 (3) 0
Diarrhea 3 (10) 3 (10) 0 0
Upper respiratory tract infection 3 (10) 1 (3) 2 (7) 0
Urinary tract infection 3 (10) 1 (3) 2 (7) 0
  1. Abbreviations: AE adverse event, AST aspartate transaminase, ALT alanine transaminase
  2. aIncludes one patient who died of acute respiratory failure (Grade 5 AE) unrelated to the study medication while on trial